Product Categories
- Category: COVID-19
- Category: Preclinical Safety
- Strategic Insights for Advancing PROTACs Toward IND Submission
- 4 Essential Safety Assessments to Consider for Peptide Preclinical Testing
- Early-Stage Considerations for PROTAC Development: From Design to Preclinical Readiness
- Early-Stage Considerations for Optimizing Respiratory Drug Development
- A Strategic Roadmap for Peptide Preclinical Studies: 3 Key Stages
- Five Ways to Ensure hERG Assays are Scientifically Reliable
- Clinical Analysis Strategies for Complement Biomarkers
- 4 Reasons Why Genetic Toxicology is Foundational to Modern Drug Development
- Five Keys to Success in Bispecific Antibody Development
- 6 Key Challenges in Oligonucleotide Development & Testing (And How to Overcome Them)
- How to Overcome 9 Key Peptide Drug Development Challenges
- 4 Analytical Methods Commonly Used in Oligonucleotide Preclinical Testing
- 3 Important DMPK Considerations for Successful Oligonucleotide Preclinical Testing
- The 4 Most Promising Therapeutic Applications for Peptide Drug Development
- Preclinical Drug Development Demystified: Your ADME to Toxicology Roadmap
- Five Pointers to Successfully Navigate the Challenges of Peptide Therapeutic Development
- Overcoming Challenges in Ocular Drug Testing with Advanced PK/PD Approaches
- What Is IVIVE? 7 FAQs About In Vitro-In Vivo Extrapolation
- Improving Bioanalytical Flexibility and Efficiency with Whole Blood Cryopreservation
- Four Essential Pointers to Navigate CNS Regulations and Safety Assessments
- Navigating the Complexities of Ocular Drug Delivery Systems
- WuXi AppTec Launches Research Book Decoding DMPK Frontiers for Novel Therapeutics
- DAR Research on ADCs Using LC-MS
- Transforming Drug Development: How Smart Compound Management Safeguards Integrity and Boosts Efficiency
- ICH M10: What the Finalized Guideline Means for Bioanalytical Scientists
- From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling
- 3 Therapeutic Considerations for the Future of Oligonucleotide Development
- 6 Factors That Can Make or Break the mRNA Therapeutic Development
- What It Takes to Optimize Analytical Strategies for ADC Development
- Hybrid-ELISA in the Bioanalysis of Oligonucleotide Drugs
- Four Ways to Unlock the Potential of Antisense Oligonucleotides in Eye Care
- Five Ways LNP-mRNA is Shaping the Future of Medicine
- How Early Safety Pharmacology Studies Accelerate Drug Development and Reduce Risk
- Why Non-GLP Studies Matter in Preclinical Drug Development
- From Molecule to IND: A Strategic Roadmap Through Preclinical Studies
- Key Challenges in Oligonucleotide Bioanalysis—And How to Overcome Them
- What Is Large Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
- 6 Strategies to Overcome PROTACs’ Developmental Challenges
- The Future of Precision Medicine: How Bioanalysis is Transforming Personalized Healthcare
- Bioanalysis of ADC Drugs by LC-MS/MS
- 5 Tips to Navigating Antisense Oligonucleotide Drug Development
- Key Toxicology Considerations for Large-Molecule Therapies
- Overcoming the challenges of preclinical evaluations for PROTACs
- Bioanalytical Strategies for Fusion Proteins
- What Is Small Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
- Making the Most of the Golden Age of Small-Molecule Oncology Drugs
- Evaluation of Immunogenicity for Oligonucleotide Drugs
- LCMS Preclinical Bioanalysis of LNPs in Advanced Therapy Drugs
- 3 DMPK Strategies for ADC Drugs
- Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies
- Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage
- Bioanalysis of GLP-1 Antagonist Drugs by Multiple Analytical Platforms
- Overcoming nonspecific binding challenges in PK assays
- Bioanalytical Strategies for Peptide-Drug Conjugates (PDCs): Optimized Approaches for the Pharmaceutical Industry
- Validating Flow Cytometry-Based Micronucleus Assays in Alternative Species
- How to Evaluate the Preclinical Safety of Oligonucleotide Drugs
- Understanding the Sensitivity and Accuracy of FOB Tests for CNS and non-CNS Targeted Compounds
- Ensuring Multi-Ion Channel Inhibition Assays are Accurate and Reliable
- Unlocking Drug Insights with Cutting-Edge Molecular Imaging Solutions
- Small vs. Large Molecule Bioanalysis: 7 Key Differences
- When to Start Subchronic & Chronic Toxicology Studies
- Clinical Bioanalysis Strategy for Antibody Drug Conjugates (ADCs)
- Biological Significance and Bioanalytical Strategies of Biomarkers – Complement Detection
- Why are GLP Toxicology Studies Important?
- Designing Juvenile Toxicology Studies: Key Considerations for Drug Development
- How Radionuclide Drug Conjugates are Transforming Cancer Treatment
- 5 Ways You Can Automate Preclinical Bioanalysis
- Targeting the Untargetable: How Oligonucleotide Drugs Address Undruggable Proteins
- The Advantages of LC-MS/MS in Optimizing ADC Bioassays
- The Essential Role of Biomarkers in Modern Medicine: From Disease Diagnosis to Treatment Optimization
- Application of Protein Biomarkers in Pharmaceutical Research and Bioanalysis Strategies
- Why Communication is Essential to Non-clinical Testing
- The Vital Role of Toxicity Studies in New Drug Development
- IND Studies: Understanding Early-Stage Regulatory Needs
- Unlocking the Potential: Navigating Non-Clinical Programs for Biotherapeutics
- Everything Drug Developers Need to Know to Prepare for IND Submissions
- Key Components of IND Study Strategy Planning
- A Step-By-Step Guide to Successful IND Studies
- Finding the Best Lab Partner for your IND Submission
- A Step Forward in Oligo Therapy: A New Assay for Testing Oligo Stability in Plasma
- Application of qPCR Technology in the Bioanalysis of Oligonucleotide Drugs
- 3 Benefits of In Vitro ADME Testing Automation
- Innovative Bioanalytical Strategies for Oligonucleotide Therapeutics: A New Frontier in American Drug Development
- 6 Types of Toxicology Studies for IND & NDA Programs
- Bridging Cultures, Breaking Barriers: WuXi AppTec Women Leading the Way in Drug Development
- Innovations in Drug Development: The Increased Utility of In Vitro Testing
- SOT’s 2024 Annual Meeting: Showcasing Scientific Advancement & Celebrating Milestones
- Is Your Drug Ready for Preclinical Toxicological Testing?
- What Toxicity Data Is Needed Before First-In-Human (FIH) Trials?
- Striking the Right Balance: Linker Design in ADC Cancer Therapies
- ELISpot Assays: The Key to Unlocking Advanced Cellular Immunity Testing
- The Crucial Role of Biomarkers in the Precision Medicine Revolution
- Acute Toxicity Studies: 3 Best Practices to Stay on Track with Your IND Timeline
- 3 Common Missteps in Nonclinical Safety Assessment Testing
- What Is IND-Enabling Testing & What Does It Include?
- Oligonucleotide Development: History, Pain Points & Bioanalytical Considerations
- Basic Questions Developers Are Asking About In Vitro-In Vivo Extrapolation
- Good Communication Essential To Successful Preclinical Testing
- Understanding Differences in Regulatory Requirements Vital to Efficient Design of Preclinical Programs
- PROTACs and Their Role in Catalyzing Health Solutions
- An Important First Step in the Design of a Preclinical Program
- Pathologists Can Move Your Drug Development Program Forward
- WuXi AppTec Grows Biomarker Capabilities with Quanterix
- 5 Questions When Planning a Nonclinical Toxicology Program for Biotherapeutics
- You’ve Got Molecules, We’ve Got Solutions
- Partner Up – A Nonclinical Talk with Toxicology Consultant, Grace Furman
- Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development
- Internal Standard Variation Case Studies: A Look into the Latest Whitepaper
- Regulatory Pathways: IND Requirement Variations Between U.S. FDA, OECD and NMPA
- Ensure a Successful Clinical Translation with DMPK Strategies
- Transitioning to Phase I Clinical Trials
- Dual Filing your IND Package: Planning Pays Off
- New U.S. FDA DDI Draft Guidance for Therapeutic Proteins
- ACT Annual Meeting: Managing Roadblocks to Success
- In Vivo PK/ADME Studies — Positioning, Planning and Best Practices
- Immunoaffinity Purification using LC-MS/MS: Comparing Two Methods
- Webinar: Practical Implications of Recent Changes to Immunogenicity Risk Assessment
- Providing Support for Drug Discovery and Non-GLP Bioanalysis
- Immunogenicity Assessment for Biologics Development: How to Reduce the Risk of a Clinical Hold
- What You Need To Know Planning for an IND Submission
- Category: Preclinical Testing
- Category: Regulatory
- Category: Regulatory Expertise
- Category: Technical Expertise
Products
- Category: COVID-19
- Category: Preclinical Safety
- Strategic Insights for Advancing PROTACs Toward IND Submission
- 4 Essential Safety Assessments to Consider for Peptide Preclinical Testing
- Early-Stage Considerations for PROTAC Development: From Design to Preclinical Readiness
- Early-Stage Considerations for Optimizing Respiratory Drug Development
- A Strategic Roadmap for Peptide Preclinical Studies: 3 Key Stages
- Five Ways to Ensure hERG Assays are Scientifically Reliable
- Clinical Analysis Strategies for Complement Biomarkers
- 4 Reasons Why Genetic Toxicology is Foundational to Modern Drug Development
- Five Keys to Success in Bispecific Antibody Development
- 6 Key Challenges in Oligonucleotide Development & Testing (And How to Overcome Them)
- How to Overcome 9 Key Peptide Drug Development Challenges
- 4 Analytical Methods Commonly Used in Oligonucleotide Preclinical Testing
- 3 Important DMPK Considerations for Successful Oligonucleotide Preclinical Testing
- The 4 Most Promising Therapeutic Applications for Peptide Drug Development
- Preclinical Drug Development Demystified: Your ADME to Toxicology Roadmap
- Five Pointers to Successfully Navigate the Challenges of Peptide Therapeutic Development
- Overcoming Challenges in Ocular Drug Testing with Advanced PK/PD Approaches
- What Is IVIVE? 7 FAQs About In Vitro-In Vivo Extrapolation
- Improving Bioanalytical Flexibility and Efficiency with Whole Blood Cryopreservation
- Four Essential Pointers to Navigate CNS Regulations and Safety Assessments
- Navigating the Complexities of Ocular Drug Delivery Systems
- WuXi AppTec Launches Research Book Decoding DMPK Frontiers for Novel Therapeutics
- DAR Research on ADCs Using LC-MS
- Transforming Drug Development: How Smart Compound Management Safeguards Integrity and Boosts Efficiency
- ICH M10: What the Finalized Guideline Means for Bioanalytical Scientists
- From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling
- 3 Therapeutic Considerations for the Future of Oligonucleotide Development
- 6 Factors That Can Make or Break the mRNA Therapeutic Development
- What It Takes to Optimize Analytical Strategies for ADC Development
- Hybrid-ELISA in the Bioanalysis of Oligonucleotide Drugs
- Four Ways to Unlock the Potential of Antisense Oligonucleotides in Eye Care
- Five Ways LNP-mRNA is Shaping the Future of Medicine
- How Early Safety Pharmacology Studies Accelerate Drug Development and Reduce Risk
- Why Non-GLP Studies Matter in Preclinical Drug Development
- From Molecule to IND: A Strategic Roadmap Through Preclinical Studies
- Key Challenges in Oligonucleotide Bioanalysis—And How to Overcome Them
- What Is Large Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
- 6 Strategies to Overcome PROTACs’ Developmental Challenges
- The Future of Precision Medicine: How Bioanalysis is Transforming Personalized Healthcare
- Bioanalysis of ADC Drugs by LC-MS/MS
- 5 Tips to Navigating Antisense Oligonucleotide Drug Development
- Key Toxicology Considerations for Large-Molecule Therapies
- Overcoming the challenges of preclinical evaluations for PROTACs
- Bioanalytical Strategies for Fusion Proteins
- What Is Small Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
- Making the Most of the Golden Age of Small-Molecule Oncology Drugs
- Evaluation of Immunogenicity for Oligonucleotide Drugs
- LCMS Preclinical Bioanalysis of LNPs in Advanced Therapy Drugs
- 3 DMPK Strategies for ADC Drugs
- Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies
- Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage
- Bioanalysis of GLP-1 Antagonist Drugs by Multiple Analytical Platforms
- Overcoming nonspecific binding challenges in PK assays
- Bioanalytical Strategies for Peptide-Drug Conjugates (PDCs): Optimized Approaches for the Pharmaceutical Industry
- Validating Flow Cytometry-Based Micronucleus Assays in Alternative Species
- How to Evaluate the Preclinical Safety of Oligonucleotide Drugs
- Understanding the Sensitivity and Accuracy of FOB Tests for CNS and non-CNS Targeted Compounds
- Ensuring Multi-Ion Channel Inhibition Assays are Accurate and Reliable
- Unlocking Drug Insights with Cutting-Edge Molecular Imaging Solutions
- Small vs. Large Molecule Bioanalysis: 7 Key Differences
- When to Start Subchronic & Chronic Toxicology Studies
- Clinical Bioanalysis Strategy for Antibody Drug Conjugates (ADCs)
- Biological Significance and Bioanalytical Strategies of Biomarkers – Complement Detection
- Why are GLP Toxicology Studies Important?
- Designing Juvenile Toxicology Studies: Key Considerations for Drug Development
- How Radionuclide Drug Conjugates are Transforming Cancer Treatment
- 5 Ways You Can Automate Preclinical Bioanalysis
- Targeting the Untargetable: How Oligonucleotide Drugs Address Undruggable Proteins
- The Advantages of LC-MS/MS in Optimizing ADC Bioassays
- The Essential Role of Biomarkers in Modern Medicine: From Disease Diagnosis to Treatment Optimization
- Application of Protein Biomarkers in Pharmaceutical Research and Bioanalysis Strategies
- Why Communication is Essential to Non-clinical Testing
- The Vital Role of Toxicity Studies in New Drug Development
- IND Studies: Understanding Early-Stage Regulatory Needs
- Unlocking the Potential: Navigating Non-Clinical Programs for Biotherapeutics
- Everything Drug Developers Need to Know to Prepare for IND Submissions
- Key Components of IND Study Strategy Planning
- A Step-By-Step Guide to Successful IND Studies
- Finding the Best Lab Partner for your IND Submission
- A Step Forward in Oligo Therapy: A New Assay for Testing Oligo Stability in Plasma
- Application of qPCR Technology in the Bioanalysis of Oligonucleotide Drugs
- 3 Benefits of In Vitro ADME Testing Automation
- Innovative Bioanalytical Strategies for Oligonucleotide Therapeutics: A New Frontier in American Drug Development
- 6 Types of Toxicology Studies for IND & NDA Programs
- Bridging Cultures, Breaking Barriers: WuXi AppTec Women Leading the Way in Drug Development
- Innovations in Drug Development: The Increased Utility of In Vitro Testing
- SOT’s 2024 Annual Meeting: Showcasing Scientific Advancement & Celebrating Milestones
- Is Your Drug Ready for Preclinical Toxicological Testing?
- What Toxicity Data Is Needed Before First-In-Human (FIH) Trials?
- Striking the Right Balance: Linker Design in ADC Cancer Therapies
- ELISpot Assays: The Key to Unlocking Advanced Cellular Immunity Testing
- The Crucial Role of Biomarkers in the Precision Medicine Revolution
- Acute Toxicity Studies: 3 Best Practices to Stay on Track with Your IND Timeline
- 3 Common Missteps in Nonclinical Safety Assessment Testing
- What Is IND-Enabling Testing & What Does It Include?
- Oligonucleotide Development: History, Pain Points & Bioanalytical Considerations
- Basic Questions Developers Are Asking About In Vitro-In Vivo Extrapolation
- Good Communication Essential To Successful Preclinical Testing
- Understanding Differences in Regulatory Requirements Vital to Efficient Design of Preclinical Programs
- PROTACs and Their Role in Catalyzing Health Solutions
- An Important First Step in the Design of a Preclinical Program
- Pathologists Can Move Your Drug Development Program Forward
- WuXi AppTec Grows Biomarker Capabilities with Quanterix
- 5 Questions When Planning a Nonclinical Toxicology Program for Biotherapeutics
- You’ve Got Molecules, We’ve Got Solutions
- Partner Up – A Nonclinical Talk with Toxicology Consultant, Grace Furman
- Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development
- Internal Standard Variation Case Studies: A Look into the Latest Whitepaper
- Regulatory Pathways: IND Requirement Variations Between U.S. FDA, OECD and NMPA
- Ensure a Successful Clinical Translation with DMPK Strategies
- Transitioning to Phase I Clinical Trials
- Dual Filing your IND Package: Planning Pays Off
- New U.S. FDA DDI Draft Guidance for Therapeutic Proteins
- ACT Annual Meeting: Managing Roadblocks to Success
- In Vivo PK/ADME Studies — Positioning, Planning and Best Practices
- Immunoaffinity Purification using LC-MS/MS: Comparing Two Methods
- Webinar: Practical Implications of Recent Changes to Immunogenicity Risk Assessment
- Providing Support for Drug Discovery and Non-GLP Bioanalysis
- Immunogenicity Assessment for Biologics Development: How to Reduce the Risk of a Clinical Hold
- What You Need To Know Planning for an IND Submission
- Category: Preclinical Testing
- Category: Regulatory
- Category: Regulatory Expertise
- Category: Technical Expertise
- COVID-19
- Preclinical Safety
- Strategic Insights for Advancing PROTACs Toward IND Submission
- 4 Essential Safety Assessments to Consider for Peptide Preclinical Testing
- Early-Stage Considerations for PROTAC Development: From Design to Preclinical Readiness
- Early-Stage Considerations for Optimizing Respiratory Drug Development
- A Strategic Roadmap for Peptide Preclinical Studies: 3 Key Stages
- Five Ways to Ensure hERG Assays are Scientifically Reliable
- Clinical Analysis Strategies for Complement Biomarkers
- 4 Reasons Why Genetic Toxicology is Foundational to Modern Drug Development
- Five Keys to Success in Bispecific Antibody Development
- 6 Key Challenges in Oligonucleotide Development & Testing (And How to Overcome Them)
- How to Overcome 9 Key Peptide Drug Development Challenges
- 4 Analytical Methods Commonly Used in Oligonucleotide Preclinical Testing
- 3 Important DMPK Considerations for Successful Oligonucleotide Preclinical Testing
- The 4 Most Promising Therapeutic Applications for Peptide Drug Development
- Preclinical Drug Development Demystified: Your ADME to Toxicology Roadmap
- Five Pointers to Successfully Navigate the Challenges of Peptide Therapeutic Development
- Overcoming Challenges in Ocular Drug Testing with Advanced PK/PD Approaches
- What Is IVIVE? 7 FAQs About In Vitro-In Vivo Extrapolation
- Improving Bioanalytical Flexibility and Efficiency with Whole Blood Cryopreservation
- Four Essential Pointers to Navigate CNS Regulations and Safety Assessments
- Navigating the Complexities of Ocular Drug Delivery Systems
- WuXi AppTec Launches Research Book Decoding DMPK Frontiers for Novel Therapeutics
- DAR Research on ADCs Using LC-MS
- Transforming Drug Development: How Smart Compound Management Safeguards Integrity and Boosts Efficiency
- ICH M10: What the Finalized Guideline Means for Bioanalytical Scientists
- From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling
- 3 Therapeutic Considerations for the Future of Oligonucleotide Development
- 6 Factors That Can Make or Break the mRNA Therapeutic Development
- What It Takes to Optimize Analytical Strategies for ADC Development
- Hybrid-ELISA in the Bioanalysis of Oligonucleotide Drugs
- Four Ways to Unlock the Potential of Antisense Oligonucleotides in Eye Care
- Five Ways LNP-mRNA is Shaping the Future of Medicine
- How Early Safety Pharmacology Studies Accelerate Drug Development and Reduce Risk
- Why Non-GLP Studies Matter in Preclinical Drug Development
- From Molecule to IND: A Strategic Roadmap Through Preclinical Studies
- Key Challenges in Oligonucleotide Bioanalysis—And How to Overcome Them
- What Is Large Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
- 6 Strategies to Overcome PROTACs’ Developmental Challenges
- The Future of Precision Medicine: How Bioanalysis is Transforming Personalized Healthcare
- Bioanalysis of ADC Drugs by LC-MS/MS
- 5 Tips to Navigating Antisense Oligonucleotide Drug Development
- Key Toxicology Considerations for Large-Molecule Therapies
- Overcoming the challenges of preclinical evaluations for PROTACs
- Bioanalytical Strategies for Fusion Proteins
- What Is Small Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
- Making the Most of the Golden Age of Small-Molecule Oncology Drugs
- Evaluation of Immunogenicity for Oligonucleotide Drugs
- LCMS Preclinical Bioanalysis of LNPs in Advanced Therapy Drugs
- 3 DMPK Strategies for ADC Drugs
- Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies
- Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage
- Bioanalysis of GLP-1 Antagonist Drugs by Multiple Analytical Platforms
- Overcoming nonspecific binding challenges in PK assays
- Bioanalytical Strategies for Peptide-Drug Conjugates (PDCs): Optimized Approaches for the Pharmaceutical Industry
- Validating Flow Cytometry-Based Micronucleus Assays in Alternative Species
- How to Evaluate the Preclinical Safety of Oligonucleotide Drugs
- Understanding the Sensitivity and Accuracy of FOB Tests for CNS and non-CNS Targeted Compounds
- Ensuring Multi-Ion Channel Inhibition Assays are Accurate and Reliable
- Unlocking Drug Insights with Cutting-Edge Molecular Imaging Solutions
- Small vs. Large Molecule Bioanalysis: 7 Key Differences
- When to Start Subchronic & Chronic Toxicology Studies
- Clinical Bioanalysis Strategy for Antibody Drug Conjugates (ADCs)
- Biological Significance and Bioanalytical Strategies of Biomarkers – Complement Detection
- Why are GLP Toxicology Studies Important?
- Designing Juvenile Toxicology Studies: Key Considerations for Drug Development
- How Radionuclide Drug Conjugates are Transforming Cancer Treatment
- 5 Ways You Can Automate Preclinical Bioanalysis
- Targeting the Untargetable: How Oligonucleotide Drugs Address Undruggable Proteins
- The Advantages of LC-MS/MS in Optimizing ADC Bioassays
- The Essential Role of Biomarkers in Modern Medicine: From Disease Diagnosis to Treatment Optimization
- Application of Protein Biomarkers in Pharmaceutical Research and Bioanalysis Strategies
- Why Communication is Essential to Non-clinical Testing
- The Vital Role of Toxicity Studies in New Drug Development
- IND Studies: Understanding Early-Stage Regulatory Needs
- Unlocking the Potential: Navigating Non-Clinical Programs for Biotherapeutics
- Everything Drug Developers Need to Know to Prepare for IND Submissions
- Key Components of IND Study Strategy Planning
- A Step-By-Step Guide to Successful IND Studies
- Finding the Best Lab Partner for your IND Submission
- A Step Forward in Oligo Therapy: A New Assay for Testing Oligo Stability in Plasma
- Application of qPCR Technology in the Bioanalysis of Oligonucleotide Drugs
- 3 Benefits of In Vitro ADME Testing Automation
- Innovative Bioanalytical Strategies for Oligonucleotide Therapeutics: A New Frontier in American Drug Development
- 6 Types of Toxicology Studies for IND & NDA Programs
- Bridging Cultures, Breaking Barriers: WuXi AppTec Women Leading the Way in Drug Development
- Innovations in Drug Development: The Increased Utility of In Vitro Testing
- SOT’s 2024 Annual Meeting: Showcasing Scientific Advancement & Celebrating Milestones
- Is Your Drug Ready for Preclinical Toxicological Testing?
- What Toxicity Data Is Needed Before First-In-Human (FIH) Trials?
- Striking the Right Balance: Linker Design in ADC Cancer Therapies
- ELISpot Assays: The Key to Unlocking Advanced Cellular Immunity Testing
- The Crucial Role of Biomarkers in the Precision Medicine Revolution
- Acute Toxicity Studies: 3 Best Practices to Stay on Track with Your IND Timeline
- 3 Common Missteps in Nonclinical Safety Assessment Testing
- What Is IND-Enabling Testing & What Does It Include?
- Oligonucleotide Development: History, Pain Points & Bioanalytical Considerations
- Basic Questions Developers Are Asking About In Vitro-In Vivo Extrapolation
- Good Communication Essential To Successful Preclinical Testing
- Understanding Differences in Regulatory Requirements Vital to Efficient Design of Preclinical Programs
- PROTACs and Their Role in Catalyzing Health Solutions
- An Important First Step in the Design of a Preclinical Program
- Pathologists Can Move Your Drug Development Program Forward
- WuXi AppTec Grows Biomarker Capabilities with Quanterix
- 5 Questions When Planning a Nonclinical Toxicology Program for Biotherapeutics
- You’ve Got Molecules, We’ve Got Solutions
- Partner Up – A Nonclinical Talk with Toxicology Consultant, Grace Furman
- Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development
- Internal Standard Variation Case Studies: A Look into the Latest Whitepaper
- Regulatory Pathways: IND Requirement Variations Between U.S. FDA, OECD and NMPA
- Ensure a Successful Clinical Translation with DMPK Strategies
- Transitioning to Phase I Clinical Trials
- Dual Filing your IND Package: Planning Pays Off
- New U.S. FDA DDI Draft Guidance for Therapeutic Proteins
- ACT Annual Meeting: Managing Roadblocks to Success
- In Vivo PK/ADME Studies — Positioning, Planning and Best Practices
- Immunoaffinity Purification using LC-MS/MS: Comparing Two Methods
- Webinar: Practical Implications of Recent Changes to Immunogenicity Risk Assessment
- Providing Support for Drug Discovery and Non-GLP Bioanalysis
- Immunogenicity Assessment for Biologics Development: How to Reduce the Risk of a Clinical Hold
- What You Need To Know Planning for an IND Submission
- Preclinical Testing
- Regulatory
- Regulatory Expertise
- Technical Expertise
